CA2698205C - Myeloperoxidase inhibitors for the treatment of multiple system atrophy and huntington's disease - Google Patents

Myeloperoxidase inhibitors for the treatment of multiple system atrophy and huntington's disease Download PDF

Info

Publication number
CA2698205C
CA2698205C CA2698205A CA2698205A CA2698205C CA 2698205 C CA2698205 C CA 2698205C CA 2698205 A CA2698205 A CA 2698205A CA 2698205 A CA2698205 A CA 2698205A CA 2698205 C CA2698205 C CA 2698205C
Authority
CA
Canada
Prior art keywords
thioxo
tetrahydro
purin
pyrrolo
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2698205A
Other languages
English (en)
French (fr)
Other versions
CA2698205A1 (en
Inventor
Hakan Eriksson
Werner Poewe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CA2698205A1 publication Critical patent/CA2698205A1/en
Application granted granted Critical
Publication of CA2698205C publication Critical patent/CA2698205C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2698205A 2007-08-23 2008-08-22 Myeloperoxidase inhibitors for the treatment of multiple system atrophy and huntington's disease Expired - Fee Related CA2698205C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95752507P 2007-08-23 2007-08-23
US95752307P 2007-08-23 2007-08-23
US60/957,525 2007-08-23
US60/957,523 2007-08-23
PCT/SE2008/050950 WO2009025618A1 (en) 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Publications (2)

Publication Number Publication Date
CA2698205A1 CA2698205A1 (en) 2009-02-26
CA2698205C true CA2698205C (en) 2016-06-21

Family

ID=40378392

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2698205A Expired - Fee Related CA2698205C (en) 2007-08-23 2008-08-22 Myeloperoxidase inhibitors for the treatment of multiple system atrophy and huntington's disease

Country Status (25)

Country Link
US (6) US20090054468A1 (enExample)
EP (1) EP2200616B1 (enExample)
JP (2) JP5247804B2 (enExample)
KR (1) KR101588464B1 (enExample)
CN (4) CN105687199A (enExample)
AU (1) AU2008289653B2 (enExample)
BR (1) BRPI0815681A2 (enExample)
CA (1) CA2698205C (enExample)
CY (1) CY1113714T1 (enExample)
DK (1) DK2200616T3 (enExample)
EA (1) EA017510B1 (enExample)
ES (1) ES2399846T3 (enExample)
HR (1) HRP20130139T1 (enExample)
IL (2) IL203738A (enExample)
ME (1) ME01510B (enExample)
MX (1) MX2010001983A (enExample)
MY (1) MY155633A (enExample)
NZ (1) NZ584135A (enExample)
PH (1) PH12014501180A1 (enExample)
PL (1) PL2200616T3 (enExample)
PT (1) PT2200616E (enExample)
RS (1) RS52665B (enExample)
SI (1) SI2200616T1 (enExample)
WO (1) WO2009025618A1 (enExample)
ZA (1) ZA201000848B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
WO2012051036A1 (en) 2010-10-11 2012-04-19 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
BR112014011254A2 (pt) 2011-11-11 2017-05-16 Pfizer 2-tiopirimidinonas
ES2587954T3 (es) * 2012-03-29 2016-10-27 Basf Se Compuestos de hetero-bicíclicos N-sustituidos y derivados para combatir plagas animales II
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
CR20170498A (es) 2015-05-05 2018-01-26 Pfizer 2-tiopirimidinonas
CA3067591A1 (en) * 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
IL272043B (en) * 2017-07-17 2022-09-01 Astrazeneca Ab mpo inhibitors for use in medicine
AU2020363903A1 (en) * 2019-10-10 2022-03-24 Biohaven Therapeutics Ltd. Prodrugs of myeloperoxidase inhibitors
AU2021230370A1 (en) * 2020-03-05 2022-10-20 Biohaven Therapeutics Ltd. Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor
WO2021226161A1 (en) * 2020-05-06 2021-11-11 Biohaven Therapeutics Ltd. Process for the preparation of verdiperstat
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
JP2025528217A (ja) 2022-08-18 2025-08-26 アストラゼネカ・アクチエボラーグ ミエロペルオキシダーゼの阻害剤
CA3266275A1 (en) * 2022-08-31 2024-03-07 Astrazeneca Ab PHARMACEUTICAL FORMULATION
EP4624473A1 (en) * 2022-12-09 2025-10-01 Shenzhen Salubris Pharmaceuticals Co., Ltd. Pyrrolo[3,2-d]pyrimidin-4-one derivative, and preparation method therefor and medical use thereof
WO2024163892A1 (en) * 2023-02-02 2024-08-08 University Of Virginia Patent Foundation Myeloperoxidase (mpo) inhibition as a treatment target for delayed cerebral injury (dci) in aneurysmal subarachnoid hemorrhage (sah)
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2025190901A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2264210T3 (es) * 1997-09-05 2006-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de xantina para el tratamiento de la isquemia cerebral.
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
KR20150080013A (ko) * 2002-01-28 2015-07-08 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료용 조성물
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
EP2029603A1 (en) * 2006-06-05 2009-03-04 Astra Zeneca AB Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Also Published As

Publication number Publication date
CN105687199A (zh) 2016-06-22
AU2008289653B2 (en) 2012-06-28
KR101588464B1 (ko) 2016-01-25
US20090054468A1 (en) 2009-02-26
HRP20130139T1 (hr) 2013-03-31
US20110207755A1 (en) 2011-08-25
BRPI0815681A2 (pt) 2015-02-18
CY1113714T1 (el) 2016-06-22
HK1145141A1 (en) 2011-04-08
US20200405724A1 (en) 2020-12-31
EP2200616B1 (en) 2012-12-26
MY155633A (en) 2015-11-13
CA2698205A1 (en) 2009-02-26
AU2008289653A1 (en) 2009-02-26
ZA201000848B (en) 2012-07-25
IL203738A (en) 2015-08-31
ME01510B (me) 2014-04-20
MX2010001983A (es) 2010-03-10
JP2010536849A (ja) 2010-12-02
CN113633641A (zh) 2021-11-12
US10772890B2 (en) 2020-09-15
JP2013151547A (ja) 2013-08-08
CN101873857A (zh) 2010-10-27
CN103638029A (zh) 2014-03-19
EP2200616A4 (en) 2010-08-25
DK2200616T3 (da) 2013-03-04
US20130059870A1 (en) 2013-03-07
EP2200616A1 (en) 2010-06-30
IL240130A0 (en) 2015-09-24
WO2009025618A1 (en) 2009-02-26
RS52665B (sr) 2013-06-28
EA201000202A1 (ru) 2010-10-29
NZ584135A (en) 2012-04-27
US20190099423A1 (en) 2019-04-04
SI2200616T1 (sl) 2013-03-29
US20140221400A1 (en) 2014-08-07
EA017510B1 (ru) 2013-01-30
PT2200616E (pt) 2013-02-27
KR20100055434A (ko) 2010-05-26
JP5247804B2 (ja) 2013-07-24
ES2399846T3 (es) 2013-04-03
PL2200616T3 (pl) 2013-04-30
PH12014501180A1 (en) 2015-08-24

Similar Documents

Publication Publication Date Title
CA2698205C (en) Myeloperoxidase inhibitors for the treatment of multiple system atrophy and huntington's disease
US10413532B2 (en) Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
Liou et al. Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor
RS50242B (sr) Primena derivata 4-h-1-benzopiran-4-ona kao inhibitora preteranog razmnožavanja ćelija glatkih mišića
US20050197385A1 (en) Use of rotigotine for treatment or prevention of dopaminergic neuron loss
CA2931345A1 (en) Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits
RU2432161C1 (ru) Новые комбинации нерамексана для лечения нейродегенеративных расстройств
WO2009025617A1 (en) Combinations containing mpo inhibitors against neuroinflammatory disorders
US11103479B2 (en) Small organic molecules for use in the treatment of neuroinflammatory disorders
HK1145141B (en) Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy
CN120346202A (zh) Ripk1抑制剂及其在治疗神经功能障碍中的用途
Lapin et al. Antiethanol effects of indol-3-ylpyruvic acid in mice
CN115364102A (zh) 一种吡咯并嘧啶类化合物的应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130821

MKLA Lapsed

Effective date: 20170822